ST Elevation (STEMI) Myocardial InfarctionNCT07261514
Correlation Between Triglyceride Glucose Index and Myocardial Injury Assessed by Cardiac Magnetic Resonance Imaging (CMR) in Patients With STEMI
An observational study of ST Elevation (STEMI) Myocardial Infarction, run by Chinese PLA General Hospital at 1 site in China.
Trial summary
This research aim is to investigate the correlation between triglyceride glucose index (TyG index) and myocardial infarct size, microcirculation obstruction (MVO) and intramyocardial hemorrhage (IMH) assessed by cardiac magnetic resonance imaging (CMR) in patients with ST-segment elevation myocardial infarction… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- ST Elevation (STEMI) Myocardial Infarction
- How many people
- 674 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2014to 2 May 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: primary PCI-treated patients with acute STEMI
Who may be able to join
- 1) patients meet diagnostic criteria for STEMI-"The priority for these patients is the implementation of reperfusion therapy as soon as possible .In the appropriate clinical context,ST-segment elevation (accessed at the J-point) indicates possible acute coronary artery in the following situations:New ST elevation at the J-point in at least two contiguous leads:·≥ 2.5 mm in men under 40years,≥2mm in males 40 years and older,or ≥1.5mmin women relatively less of age in leads V2-V3,and/or ≥1mm in the other leads (in the absence of left ventricular hypertrophy or left bundle branch block) Post-STEMI reperfusion with PCI, diagnosis and treatment strategy in accordance with current diagnosis and treatment standards and guidelines27" and complete pPCI within 48h-"" diagnostic strategy meets current diagnostic criteria and guidelines;2) KillIP<3 and consent to CMR examination and follow-up observation, and CMR examination is completed within 7 days after surgery. 3) Monitor baseline blood glucose and baseline triglycerides during admission.
- Exclusion criteria: 1) Patients with NSTEMI 2) Lack of clinical data 3) Presence of contraindications to CMR examination-such as implantable cardiac pacemaker, clo gadolinium contrast agent or renal insufficiency; meanwhile, patients with Killip IV cardiac function or clinical instability, and patients with valvular disease, congenital heart disease, pulmonary hypertension, cardiomyopathy history, persistent atrial fibrillation, etc. affecting cardiac structure and function parameters were excluded; Patients with previous history of myocardial infarction, coronary artery intervention and coronary artery bypass grafting were also excluded; patients with severe clinical diseases such as severe hematological diseases, infectious diseases, malignant tumors, liver and kidney failure, and mental disorders or intellectual disabilities who could not cooperate with examination and follow-up; 4) patients with poor MRI quality or sequence deletion were not included in the study.
Who cannot join
- Contraindications of CMR examination, such as implantable cardiac pacemaker, claustrophobia, allergy to gadolinium contrast agent or renal insufficiency; meanwhile, patients with Killip IV cardiac function or unstable clinical condition, as well as patients with valve disease, congenital heart disease, pulmonary hypertension, cardiomyopathy history, persistent atrial fibrillation, etc. affecting cardiac structure and function parameters shall be excluded; Patients with a history of myocardial infarction, coronary artery intervention, or coronary artery bypass grafting were also excluded. Patients with severe hematological diseases, infectious diseases, malignant tumors, liver and kidney failure, mental disorders or intellectual disabilities who could not cooperate with examination and follow-up, or poor or missing MRI images were not included in the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Correlation Between Triglyceride Glucose Index and Myocardial Infarct Size, Microcirculation Obstruction and Intramyocardial Hemorrhage in Patients With ST-segment Elevation Myocardial Infarction.
This research aim is to investigate the correlation between triglyceride glucose index (TyG index) and myocardial infarct size, microcirculation obstruction (MVO) and intramyocardial hemorrhage (IMH) assessed by cardiac magnetic resonance imaging (CMR) in patients with ST-segment elevation myocardial infarction (STEMI), and to evaluate its value as a potential predictor of myocardial injury.To further determine the influence of TyG index on the prognosis of STEMI patients after PCI.This cohort included 674 patients with STEMI undergoing primary percutaneous coronary intervention (pPCI). Baseline clinical data were collected and cardiac magnetic resonance imaging was performed approximately 7 days after Acute Myocardial Infarction(AMI). Patients were divided into three groups according to the TyG index , namely high TyG index group, medium TyG index group and low TyG index group. Multiple linear regression, Pearson/Spearman correlation analysis and Logistics regression analysis were used to analyze the correlation between TyG index and myocardial infarct size, microcirculation obstruction and intramyocardial hemorrhage.Eventually, we came to the conclusion that the TyG index was independently associated with severity of myocardial injury after STEMI as assessed by CMR. TyG index is not only an independent predictor of microcirculation disturbance in STEMI patients, but also significantly correlated with poor cardiovascular prognosis. is a powerful marker for stratifying risk of adverse cardiovascular events.
- Keywords
- ST-segment elevation Myocardial Infarction, triglyceride glucose index, Cardiac magnetic resonance, myocardial infarct size, intramyocardial hemorrhage, microvascular obstruction
- Medical subject headings
- ST Elevation Myocardial Infarction, Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| low TyG index group | Patients with a TyG index below 1.41 were categorized into the low TyG group. | |
| medium TyG index | Patients with a TyG index between 1.41 and 1.96 were categorized into the medium TyG group. | |
| high TyG index group | Patients with a TyG index greater than 1.96 were categorized into the high TyG index group. |
What is being measured
The primary outcome is the main question the study is designed to answer.
major adverse cardiovascular events
Death , recurrence of myocardial infarction, heart failure after discharge
Measured: 4 years after discharge
Secondary outcomes (3)
myocardial infarct size
LGE sequences are acquired from CMR .The LGE images were analyzed manually or semi-automatically with software tools to calculate the size or volume of the infarct area .
Measured: Cardiac MRI within 7 days after surgery
Microvascular occlusion
T1-weighted sequences are acquired from CMR and analyzed by software.Identified by early or late gadolinium-enhanced imaging using T1-weighted sequences with high inversion times
Measured: Cardiac MRI within 7 days after surgery
Intramyocardial hemorrhage (IMH)
IMH was detected by T2-weighted imaging or T2 mapping, identified using low signal areas.
Measured: Cardiac MRI within 7 days after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2025
- Study start1 Jan 2014
- Primary completion31 Dec 2023
- Study completion2 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ST Elevation (STEMI) Myocardial InfarctionStudies of the same condition, open and under way.
- More trials run by Chinese PLA General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 674 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chinese PLA General Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Beijing Anzhen Hospital, Beijing Chao Yang Hospital, Second Affiliated Hospital of Nanchang University, First People's Hospital of Yulin, Wuhan Asia Heart Hospital, Zunyi Medical College
- Responsible party
- Principal investigator, Qian geng, Chinese PLA General Hospital
- Investigators
- geng qian, Study director, Chinese PLA General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07261514
- Sponsor's protocol ID
- 2025QG-TyG index
- Status last verified
- Jan 2014
- First submitted
- 22 Nov 2025
- Last updated
- 3 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation Between Triglyceride Glucose Index and Myocardial Infarct Size, Microcirculation Obstruction and Intramyocardial Hemorrhage in Patients With ST-segment Elevation Myocardial Infarction.
- ClinicalTrials.gov ID
- NCT07261514
- Acronym / sponsor ID
- 2025QG-TyG index
- Keywords
- ST-segment elevation Myocardial Infarction, triglyceride glucose index, Cardiac magnetic resonance, myocardial infarct size, intramyocardial hemorrhage, microvascular obstruction
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 674 participants (actual)
- Lead sponsor
- Chinese PLA General HospitalUniversity, hospital or other
- Collaborators
- Beijing Anzhen Hospital, Beijing Chao Yang Hospital, Second Affiliated Hospital of Nanchang University, First People's Hospital of Yulin, Wuhan Asia Heart Hospital, Zunyi Medical College
- Study start
- 1 Jan 2014 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 2 May 2024 (actual)
- First posted
- 3 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research aim is to investigate the correlation between triglyceride glucose index (TyG index) and myocardial infarct size, microcirculation obstruction (MVO) and intramyocardial hemorrhage (IMH) assessed by cardiac magnetic resonance imaging (CMR) in patients with ST-segment elevation myocardial infarction (STEMI), and to evaluate its value as a potential predictor of myocardial injury.To further determine the influence of TyG index on the prognosis of STEMI patients after PCI.This cohort included 674 patients with STEMI undergoing primary percutaneous coronary intervention (pPCI). Baseline clinical data were collected and cardiac magnetic resonance imaging was performed approximately 7 days after Acute Myocardial Infarction(AMI). Patients were divided into three groups according to the TyG index , namely high TyG index group, medium TyG index group and low TyG index group. Multiple linear regression, Pearson/Spearman correlation analysis and Logistics regression analysis were used to analyze the correlation between TyG index and myocardial infarct size, microcirculation obstruction and intramyocardial hemorrhage.Eventually, we came to the conclusion that the TyG index was independently associated with severity of myocardial injury after STEMI as assessed by CMR. TyG index is not only an independent predictor of microcirculation disturbance in STEMI patients, but also significantly correlated with poor cardiovascular prognosis. is a powerful marker for stratifying risk of adverse cardiovascular events.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| low TyG index group | – | –Patients with a TyG index below 1.41 were categorized into the low TyG group. |
| medium TyG index | – | –Patients with a TyG index between 1.41 and 1.96 were categorized into the medium TyG group. |
| high TyG index group | – | –Patients with a TyG index greater than 1.96 were categorized into the high TyG index group. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- primary PCI-treated patients with acute STEMI
Key inclusion criteria (2 listed)
- 1) patients meet diagnostic criteria for STEMI-"The priority for these patients is the implementation of reperfusion therapy as soon as possible .In the appropriate clinical context,ST-segment elevation (accessed at the J-point) indicates possible acute coronary artery in the following situations:New ST elevation at the J-point in at least two contiguous leads:·≥ 2.5 mm in men under 40years,≥2mm in males 40 years and older,or ≥1.5mmin women relatively less of age in leads V2-V3,and/or ≥1mm in the other leads (in the absence of left ventricular hypertrophy or left bundle branch block) Post-STEMI reperfusion with PCI, diagnosis and treatment strategy in accordance with current diagnosis and treatment standards and guidelines27" and complete pPCI within 48h-"" diagnostic strategy meets current diagnostic criteria and guidelines;2) KillIP<3 and consent to CMR examination and follow-up observation, and CMR examination is completed within 7 days after surgery. 3) Monitor baseline blood glucose and baseline triglycerides during admission.
- Exclusion criteria: 1) Patients with NSTEMI 2) Lack of clinical data 3) Presence of contraindications to CMR examination-such as implantable cardiac pacemaker, clo gadolinium contrast agent or renal insufficiency; meanwhile, patients with Killip IV cardiac function or clinical instability, and patients with valvular disease, congenital heart disease, pulmonary hypertension, cardiomyopathy history, persistent atrial fibrillation, etc. affecting cardiac structure and function parameters were excluded; Patients with previous history of myocardial infarction, coronary artery intervention and coronary artery bypass grafting were also excluded; patients with severe clinical diseases such as severe hematological diseases, infectious diseases, malignant tumors, liver and kidney failure, and mental disorders or intellectual disabilities who could not cooperate with examination and follow-up; 4) patients with poor MRI quality or sequence deletion were not included in the study.
Key exclusion criteria (1 listed)
- Contraindications of CMR examination, such as implantable cardiac pacemaker, claustrophobia, allergy to gadolinium contrast agent or renal insufficiency; meanwhile, patients with Killip IV cardiac function or unstable clinical condition, as well as patients with valve disease, congenital heart disease, pulmonary hypertension, cardiomyopathy history, persistent atrial fibrillation, etc. affecting cardiac structure and function parameters shall be excluded; Patients with a history of myocardial infarction, coronary artery intervention, or coronary artery bypass grafting were also excluded. Patients with severe hematological diseases, infectious diseases, malignant tumors, liver and kidney failure, mental disorders or intellectual disabilities who could not cooperate with examination and follow-up, or poor or missing MRI images were not included in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
major adverse cardiovascular events
Time frame: 4 years after discharge
Death , recurrence of myocardial infarction, heart failure after discharge
3 secondary outcomes
myocardial infarct size
Time frame: Cardiac MRI within 7 days after surgery
Microvascular occlusion
Time frame: Cardiac MRI within 7 days after surgery
Intramyocardial hemorrhage (IMH)
Time frame: Cardiac MRI within 7 days after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2025.
Related trials for ST Elevation (STEMI) Myocardial Infarction
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
RecruitingPhase 2
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction, Reperfusion Injury
Not yet recruitingObservational study
Incremental Prognostic Utility of CBC-derived Inflammatory Indices After Incomplete Coronary Revascularization: Association With 12-months Cardiovascular Outcomes
STEMI, High Risk NSTEMI
RecruitingObservational study
SuperSaturated Oxygen Comprehensive Observational Registry
STEMI - ST Elevation Myocardial Infarction, AMI
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
geng qian study director
Chinese PLA General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of ST Elevation (STEMI) Myocardial Infarction, run by Chinese PLA General Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
major adverse cardiovascular events (time frame: 4 years after discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2025.